Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.64
PLX's Cash to Debt is ranked lower than
83% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. PLX: 0.64 )
Ranked among companies with meaningful Cash to Debt only.
PLX' s 10-Year Cash to Debt Range
Min: 0.64  Med: 10000.00 Max: No Debt
Current: 0.64
Equity to Asset -0.99
PLX's Equity to Asset is ranked lower than
97% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PLX: -0.99 )
Ranked among companies with meaningful Equity to Asset only.
PLX' s 10-Year Equity to Asset Range
Min: -0.99  Med: -0.09 Max: 0.8
Current: -0.99
-0.99
0.8
F-Score: 3
Z-Score: -5.08
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -152.69
PLX's Operating margin (%) is ranked lower than
58% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. PLX: -152.69 )
Ranked among companies with meaningful Operating margin (%) only.
PLX' s 10-Year Operating margin (%) Range
Min: -8239.43  Med: -335.58 Max: -14.61
Current: -152.69
-8239.43
-14.61
Net-margin (%) -185.91
PLX's Net-margin (%) is ranked lower than
61% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. PLX: -185.91 )
Ranked among companies with meaningful Net-margin (%) only.
PLX' s 10-Year Net-margin (%) Range
Min: -8103.09  Med: -338.49 Max: -14.27
Current: -185.91
-8103.09
-14.27
ROA (%) -34.58
PLX's ROA (%) is ranked lower than
57% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. PLX: -34.58 )
Ranked among companies with meaningful ROA (%) only.
PLX' s 10-Year ROA (%) Range
Min: -372.46  Med: -30.24 Max: 1.59
Current: -34.58
-372.46
1.59
ROC (Joel Greenblatt) (%) -197.43
PLX's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. PLX: -197.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PLX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -988.83  Med: -200.12 Max: -4.83
Current: -197.43
-988.83
-4.83
Revenue Growth (3Y)(%) 17.00
PLX's Revenue Growth (3Y)(%) is ranked higher than
75% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. PLX: 17.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PLX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 236.2
Current: 17
0
236.2
EBITDA Growth (3Y)(%) -14.90
PLX's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. PLX: -14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PLX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -53.6  Med: -13.35 Max: 84.2
Current: -14.9
-53.6
84.2
EPS Growth (3Y)(%) -9.40
PLX's EPS Growth (3Y)(%) is ranked lower than
53% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. PLX: -9.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PLX' s 10-Year EPS Growth (3Y)(%) Range
Min: -49.7  Med: -9.25 Max: 54.6
Current: -9.4
-49.7
54.6
» PLX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

PLX Guru Trades in Q2 2013

First Eagle Investment 500,000 sh (unchged)
Manning & Napier Advisors, Inc 159,710 sh (-88.85%)
» More
Q3 2013

PLX Guru Trades in Q3 2013

First Eagle Investment 500,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
» More
Q4 2013

PLX Guru Trades in Q4 2013

First Eagle Investment 700,000 sh (+40.00%)
» More
Q1 2014

PLX Guru Trades in Q1 2014

First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 8.82
PLX's P/S is ranked higher than
50% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. PLX: 8.82 )
Ranked among companies with meaningful P/S only.
PLX' s 10-Year P/S Range
Min: 8.76  Med: 35.13 Max: 748
Current: 8.82
8.76
748
Current Ratio 2.11
PLX's Current Ratio is ranked lower than
73% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. PLX: 2.11 )
Ranked among companies with meaningful Current Ratio only.
PLX' s 10-Year Current Ratio Range
Min: 1.72  Med: 4.79 Max: 72.77
Current: 2.11
1.72
72.77
Quick Ratio 1.86
PLX's Quick Ratio is ranked lower than
70% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. PLX: 1.86 )
Ranked among companies with meaningful Quick Ratio only.
PLX' s 10-Year Quick Ratio Range
Min: 1.45  Med: 4.79 Max: 72.77
Current: 1.86
1.45
72.77
Days Inventory 316.50
PLX's Days Inventory is ranked lower than
87% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. PLX: 316.50 )
Ranked among companies with meaningful Days Inventory only.
PLX' s 10-Year Days Inventory Range
Min: 24.15  Med: 96.76 Max: 403.33
Current: 316.5
24.15
403.33
Days Sales Outstanding 47.73
PLX's Days Sales Outstanding is ranked higher than
64% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. PLX: 47.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
PLX' s 10-Year Days Sales Outstanding Range
Min: 14.95  Med: 66.29 Max: 2016.91
Current: 47.73
14.95
2016.91

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.27
PLX's Price/Median PS Value is ranked higher than
92% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. PLX: 0.27 )
Ranked among companies with meaningful Price/Median PS Value only.
PLX' s 10-Year Price/Median PS Value Range
Min: 0.01  Med: 0.65 Max: 18.74
Current: 0.27
0.01
18.74
Earnings Yield (Greenblatt) (%) -14.11
PLX's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. PLX: -14.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PLX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -16.4  Med: 0.00 Max: 0
Current: -14.11
-16.4
0

Analyst Estimate

Dec15
Revenue(Mil) 61
EPS($) -0.17
EPS without NRI($) -0.17

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PLX.Israel, PBD.Germany,
Protalix BioTherapeutics Inc was originally incorporated in the State of Florida in April 1992. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx. Using its ProCellEx system, it is developing a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. Its initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company has developed ElelysoTM, its first drug product, ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The Company is now also applying the properties of its ProCellEx system for the oral delivery of therapeutic proteins. The Company relies on a single approved supplier for certain materials relating to the current expression of its proprietary biotherapeutic proteins through ProCellEx. It faces competition from companies with approved treatments of Gaucher disease. Some such companies include iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH. The Company has 94 pending patent applications and one joint pending patent application with a third party. The Company is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.
» More Articles for PLX

Headlines

Articles On GuruFocus.com
Avago Technologies' Memory, FBAR, and Connectivity Business Will Take It Higher Oct 23 2014 
Weekly CFO Sells Highlight: AXP, CRAY, PLX, KMB, ITW, CATM, CAR May 07 2012 
Protalix BioTherapeutics Inc Reports Operating Results (10-K) Feb 23 2011 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Nov 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Oct 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Sep 08 2010 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 05 2010 
Protalix BioTherapeutics Inc (PLX) CEO and President David Aviezer sells 244,238 Shares Oct 21 2009 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 150,000 Shares Oct 19 2009 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 03 2009 

More From Other Websites
PROTALIX BIOTHERAPEUTICS, INC. Financials Aug 22 2015
Protalix reports 2Q loss Aug 10 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 10 2015
Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results Aug 10 2015
Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results for PRX-106 Oral Anti-TNF Aug 03 2015
CollPlant Names Shomrat Shurtz Senior Director of Business Development Jul 28 2015
Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis... Jun 12 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 07 2015
Surging Earnings Estimates Signal Good News for Protalix BioTherapeutics (PLX) - Tale of the Tape Apr 10 2015
Protalix BioTherapeutics (PLX) Shares March Higher, Can It Continue? - Tale of the Tape Apr 09 2015
Why Protalix BioTherapeutics (PLX) Stock Might be a Great Pick - Tale of the Tape Apr 02 2015
Protalix BioTherapeutics (PLX): An Off-the-Radar Potential Winner - Tale of the Tape Mar 20 2015
Protalix reports 4Q loss Mar 12 2015
Protalix reports 4Q loss Mar 12 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 12 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Feb 12 2015
Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog Feb 04 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Feb 02 2015
Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning Jan 08 2015
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Jan 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK